Azathioprine is a widely used immunosuppressive drug primarily indicated for preventing organ transplant rejection and treating autoimmune diseases such as Rheumatoid Arthritis and Inflammatory Bowel Disease. It works by inhibiting purine synthesis, thereby reducing the proliferation of immune cells like T and B lymphocytes, which helps control abnormal immune responses. Azathioprine was first synthesized in the 1950s by researchers at Wellcome Research Laboratories as part of efforts to find effective agents for immunosuppression in organ transplantation. Over subsequent decades, extensive clinical studies established its efficacy and safety profile, leading to widespread adoption in both transplantation medicine and autoimmune disorder management. Its development marked a major milestone in immunopharmacology, offering an alternative to more toxic or less specific immunosuppressive therapies.
